Deciphera Pharmaceuticals... (DCPH)
NASDAQ: DCPH
· Real-Time Price · USD
25.59
0.02 (0.08%)
At close: Jun 10, 2024, 10:00 PM
Deciphera Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 174.91M | 163.36M | 151.41M | 144.07M | 138.26M | 134.04M | 121.89M | 109.14M | 100.22M | 96.15M | 91.44M | 83.66M | 67.18M |
Cost of Revenue | 6.93M | 3.73M | 5.19M | 7.25M | 8.88M | 8.77M | 6.04M | 3.62M | 3.09M | 2.93M | 2.54M | 1.71M | 447K |
Gross Profit | 167.98M | 159.62M | 146.22M | 136.82M | 129.38M | 125.27M | 115.85M | 105.52M | 97.12M | 93.22M | 88.89M | 81.95M | 66.73M |
Operating Income | -206.55M | -210.96M | -206.88M | -198.07M | -189.09M | -183.5M | -224.75M | -259.53M | -286.26M | -300.08M | -274.68M | -259M | -257.42M |
Interest Income | 16.56M | 16.45M | 13.89M | 11.63M | 8.14M | 4.49M | 2.57M | 733K | 87K | 283K | 536K | 832K | 2.44M |
Pretax Income | -189.99M | -194.51M | -192.99M | -186.45M | -180.95M | -178.23M | -221.39M | -258.19M | -285.56M | -299.96M | -274.31M | -258.17M | -254.98M |
Net Income | -190.42M | -194.94M | -193.69M | -183.47M | -176.52M | -173.02M | -215.48M | -255.95M | -284.77M | -299.96M | -274.31M | -258.17M | -254.98M |
Selling & General & Admin | 137.79M | 136.46M | 129.51M | 126.28M | 123.3M | 120.17M | 125.12M | 130.62M | 133.83M | 136.25M | 129.17M | 123.79M | 120.89M |
Research & Development | 236.74M | 234.12M | 223.59M | 208.61M | 195.17M | 187.82M | 214.69M | 233.65M | 248.77M | 257.04M | 234.4M | 217.17M | 203.26M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 374.53M | 370.58M | 353.1M | 334.89M | 318.47M | 307.99M | 339.81M | 364.27M | 382.6M | 393.29M | 363.57M | 340.95M | 324.16M |
Interest Expense | 3.65M | 3.65M | 1.95M | 3.79M | 4.51M | 4.51M | 2.57M | 903K | 257K | 453K | 706K | 832K | 2.44M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 381.46M | 374.31M | 358.29M | 342.14M | 327.35M | 316.76M | 345.85M | 367.89M | 385.69M | 396.23M | 366.11M | 342.67M | 324.6M |
Income Tax Expense | -34K | -34K | 235K | -2.98M | -4.43M | -5.21M | -5.91M | -2.23M | -777K | 6K | 259K | 555K | 555K |
Shares Outstanding (Basic) | 87.39M | 86.7M | 85.79M | 85.02M | 82.68M | 76.44M | 78.21M | 71.77M | 58.62M | 58.49M | 58.11M | 57.99M | 57.75M |
Shares Outstanding (Diluted) | 87.39M | 86.7M | 85.79M | 85.02M | 82.68M | 76.44M | 78.21M | 72.13M | 58.62M | 58.49M | 58.11M | 57.99M | 57.75M |
EPS (Basic) | -2.21 | -2.29 | -2.35 | -2.27 | -2.28 | -2.47 | -3.38 | -4.25 | -4.88 | -5.15 | -4.75 | -4.51 | -4.5 |
EPS (Diluted) | -2.21 | -2.29 | -2.35 | -2.27 | -2.28 | -2.47 | -3.38 | -4.25 | -4.88 | -5.15 | -4.75 | -4.51 | -4.5 |
EBITDA | -203.92M | -209.93M | -206.31M | -196.76M | -187.53M | -181.16M | -222.4M | -257.17M | -283.97M | -297.84M | -271.49M | -255.61M | -252.6M |
EBIT | -198.42M | -149.57M | -149.73M | -137.25M | -126.8M | -174.48M | -219.62M | -258.08M | -286.1M | -299.52M | -273.6M | -257.34M | -252.54M |
Depreciation & Amortization | 3.09M | 2.1M | 2.25M | 2.52M | 2.77M | 2.95M | 3.13M | 3.14M | 3.06M | 3.01M | 2.93M | 2.84M | 2.58M |